Hong Kong stocks fluctuated | China-Affiliated Brokerage stocks fell broadly in the early session, as the retreat of trading styles affected market risk appetite. Institutions stated that Brokerage valuations do not reflect expectations of profit improvem

China-Affiliated Brokerage stocks were broadly down in the morning session. As of the time of writing, China Merchants (06099) fell by 4.22% to HKD 13.62; Guolian (01456) dropped by 2.98% to HKD 3.91; Everbright (06178) decreased by 2.06% to HKD 7.12; and CSC (06066) declined by 1.94% to HKD 9.09.

Zhitong FinanceJan 7 22:01 ET

Hong Kong stocks movement | China-Affiliated Brokerage shares continue to decline, with multiple stocks dropping more than 3%. Institutions state that domestic and international events will face important intersections.

China-Affiliated Brokerage stocks continue to decline. As of the time of writing, CC SECURITIES (01375) is down 3.73%, priced at 1.55 HKD; China Merchants (06099) is down 3.5%, priced at 14.32 HKD; Guolian (01456) is down 3.1%, priced at 4.07 HKD; Everbright (06178) is down 1.61%, priced at 7.32 HKD.

Zhitong FinanceJan 3 02:06 ET

Everbright (06178): The Investor Service Center received special authorization to apply to the Nanjing Intermediate People's Court in Jiangsu Province to participate in the litigation as a representative.

Everbright Securities (06178) announced that on December 30, 2024, the China Securities Small Investor Service Center Limited...

Zhitong FinanceJan 1 05:49 ET

Chinese Securities Body Joins Ordinary Representative Litigation in Jin Tong Ling Tech Case

MT NewswiresDec 31, 2024 02:18 ET

Express News | Everbright Securities - on Dec 29, High People's Court of Jiangsu Province Rejected Reconsideration Application, Upheld Original Ruling

ReutersDec 30, 2024 08:48 ET

Everbright: Maintains the "Buy" rating for ASCLETIS-B. ASC47 combined with semaglutide shows superior effects.

Everbright released a research report stating that ASCLETIS-B (01672) is actively laying out its strategies in the MASH and weight loss sectors, and its progress is among the best in the country. Considering the company's effective control over various expenses, the net income forecast for 2024-2025 has been adjusted to -0.261/-0.313 billion yuan (previously -0.284/-0.34 billion yuan), and a new net income forecast for 2026 is -0.322 billion yuan, maintaining a "Buy" rating. The company released experimental data on the weight loss and muscle gain treatment drug ASC47 combined with semaglutide in obese mice; this drug is a fat-targeting, once-a-month subcutaneous injection of a thyroid hormone receptor β agonist.

Sina Hong Kong StocksDec 24, 2024 03:33 ET